

REMARKS***Specification Amendment***

The title of the invention has been changed to the more descriptive title, 2,4-DIAMINO PYRIMIDINE COMPOUNDS HAVING ANTI-CELL PROLIFERATIVE ACTIVITY, which is the title proposed by the Examiner in parent Application No. 09/763,703 (now abandoned).

Claim Amendments

Original claims 1-13 have been cancelled, and replaced with new claims 14-25. Claims 14-25 are identical to claims 14-25 that were allowed in parent Application No. 09/763,703 (now abandoned), except that they are further limited by the removal of the group “phenyl-(1-4C)alkoxy” from the optional substituents on Q₁ [claim 14, lines 57 and 62; claim 15, lines 41 and 46], to further distinguish the present claims from Davis, WO97/19065 (cited in the International Search Report and also in the Information Disclosure Statement accompanying this Preliminary Amendment). One distinction of the present claims over the disclosure of Davis is that the presently claimed compounds can have only one group linked via an oxygen linker on Q₁ (the group of formula (Ia) when -X- is oxygen), whereas the phenyl group at the 2-position of the pyrimidine ring in Davis must always be substituted by at least two groups linked by an oxygen linker. It recently came to applicants’ attention that the optional “phenyl-(1-4C)alkoxy” permitted on Q₁ in the allowed claims of the parent application could provide a second group on Q₁ linked via an oxygen linker. It is believed that the deletion of “phenyl-(1-4C)alkoxy” from the optional substituents on Q₁ in the present

claims now avoids any possible generic overlap between the present claims and the Davis reference.

Present claims 14-25 also differ from claims 14-25 that were allowed in the parent application with respect to the removal of "CH₂" from the definition of "X" in formula (Ia) [claim 14, line 29; claim 15, line 13; claim 16, line 12; claim 23, line 1 of subpart e)]. This amendment has been made to more clearly distinguish the present claims from, and avoid any overlap with, the claims of related co-pending Application No. 10/203,025, which was recently allowed.

No new matter is added by the above amendments, and entry thereof is believed to be in order, and is respectfully requested. Following entry of the above amendments, claims 14-25 will be pending in this application.


Information Disclosure Statement

The Examiner's attention is called to the Information Disclosure Statement and accompanying form PTO-1449 submitted herewith. The Information Disclosure Statement provides an updated list of U.S. applications of Applicants' assignee (and any patents issued thereon) which are technically related to the present application. The accompanying PTO-1449 formally cites each of the references cited in the parent application, so that each reference will be printed on the patent issuing from this continuing application. Inasmuch as the Examiner acknowledged receipt and consideration of each of the references cited in the parent application, duplicate copies are not being provided herewith, per MPEP ¶ 609.I.A.2. Additionally, for the Examiner's convenience, each U.S. patent issued on one of the

technically related applications listed above is also listed on the form PTO-1449, and a copy of each of the six additional U.S. patent references is being submitted herewith.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: September 7, 2004
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001